Nobivac® DHPPi lyophilisate for suspension for injection for dogs
Nobivac DHPPi provides immunisation of dogs against canine distemper, hepatitis (canine adenovirus), canine parvovirus and canine parainfluenza and is typically given in combination with a Nobivac leptospirosis vaccine (Nobivac Lepto 2 or Nobivac L4). It is recommended that puppies may be immunised from 6 weeks of age, 2-4 weeks apart, with a second dose from 10 weeks of age. The onset of immunity for canine distemper virus, canine adenovirus and canine parvovirus is 1 week after the second vaccination in a primary vaccination course. The onset of immunity for canine parainfluenza virus is 4 weeks. In dogs over 10 weeks of age or older a single dose is likely to be sufficient to establish active immunity to canine distemper, infectious canine hepatitis and canine parvovirus.
Immunity provided against these core diseases is long lasting, with a minimum duration of immunity recommended revaccination interval of 3 years, however it is recommended that dogs be vaccinated against canine parainfluenza virus every year. An annual healthcheck and vaccination against canine leptospirosis is still recommended for all dogs.
Presentation
Off-white or cream-coloured lyophilisate for suspension for injection
Active ingredients
Nobivac DHPPi contains live, attenuated, freeze dried canine distemper virus, canine adenovirus-2 (CAV2), canine parvovirus and canine parainfluenza virus.
Each dose of 1 ml contains:
Live canine distemper virus (CDV), strain Onderstepoort ≥ 104.0 TCID50*
Live canine adenovirus type 2 (CAV2), strain Manhattan LPV3 ≥ 104.0 TCID50*
Live canine parvovirus (CPV), strain 154 ≥ 107.0 TCID50*
Live canine parainfluenza virus (CPi), strain Cornell ≥ 105.5 TCID50*
*TCID50= Median Tissue Culture Infective Dose
Target species
Dogs
Indications for use
Nobivac DHPPi is indicated for active immunisation of dogs to:
- Prevent mortality and clinical signs caused by canine distemper virus infection
- Reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection
- Prevent mortality, clinical signs and viral excretion following canine parvovirus infection
- Reduce clinical signs and viral excretion caused by canine parainfluenza virus infection
- Reduce clinical signs of respiratory disease and viral excretion following adenovirus type 2 infection
Packaging
Nobivac DHPPi is presented in plastic boxes containing 10 or 50 single dose vials. Nobivac Solvent is packaged separately.
Legal category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Date of preparation: March 2023
Nobivac® Lepto 2 contains inactivated Leptospira interrogans serogroup Canicola (strain Ca-12-000) and Icterohaemorrhagiae (strain 820K). POM-V.
Nobivac® L4 contains inactivated Leptospira strains: L. interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000), L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001), L. interrogans serogroup Australis serovar Bratislava (strain As-05-073) and L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005). POM-V.
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
MSD Animal Health UK Limited, Walton Manor, Walton, Milton Keynes, MK7 7AJ, UK
Registered in England & Wales no. 946942